Editas Medicine Announces Third Quarter 2018 Results and Update
Filed IND application for EDIT-101 with
Favorable Appeals Court ruling affirms strength of foundational intellectual property
Oral presentation at ASH Annual Meeting to highlight novel Sickle Cell Disease and Beta-Thalassemia program
Strong balance sheet with
“The filing of the IND for EDIT-101 for the treatment of LCA10 marks a significant milestone for Editas and brings us closer to helping people living with this devastating disease,” said
Recent Achievements and Outlook
- Filed EDIT-101 Investigational New Drug (IND) application in October with
U.S. Food and Drug Administration (FDA ) for treatment of Leber Congenital Amaurosis type 10 (LCA10). In addition, theNational Institutes of Health (NIH) determined that aRecombinant DNA Advisory Committee review of the protocol for the Phase 1/2 trial of EDIT-101 was not necessary, and the protocol is now registered with the NIH. The Company expects to treat 10 to 20 patients in this open label, dose escalation study in order to evaluate the safety and efficacy of EDIT-101.
Allergan andEditas Medicine to co-develop and equally share profits and losses from EDIT-101 in the U.S. In the third quarter,Allergan Pharmaceuticals International Limited (Allergan ) exercised its option to develop and commercialize EDIT-101 under the strategic alliance formed inMarch 2017 .Allergan paid an optionexercise fee of$15 million , which was recorded in the third quarter. In addition,Editas Medicine is eligible to receive a$25 million milestone payment fromAllergan upon clearance of the IND application for EDIT-101.Editas Medicine also exercised its option in the third quarter to co-develop and equally share profits and losses in the U.S. for EDIT-101.
- Novel approach to Sickle Cell Disease and Beta-Thalassemia to be highlighted in an oral presentation at the 60th
American Society of Hematology (ASH) Annual Meeting.Editas Medicine will present pre-clinical in vivo data comparing its novel gene editing strategy to reactivate fetal hemoglobin (HbF) by editing the beta-globin locus to strategies that edit the BCL11A erythroid enhancer (BCL11Ae). In this mouse study, editing the beta-globin locus upregulated HbF with superior repopulation of red blood cell precursors as compared to editing BCL11Ae.
- Federal Appeals Court ruling affirms strength of foundational CRISPR/Cas9 intellectual property.
The U.S. Court of Appeals for the Federal Circuit (Appeals Court) upheld the U.S. Patent and Trademark Office no interference-in-fact decision concerning certain CRISPR/Cas9 patentsEditas Medicine exclusively licenses fromBroad Institute, Inc. The patents broadly cover CRISPR/Cas9 gene editing in eukaryotic cells, which the Company believes is essential to making CRISPR medicines.
- Added key leadership in oncology and engineered cell medicines.
Richard A. Morgan , Ph.D., a leading expert in gene therapy and oncology, joinedEditas Medicine as Senior Vice President of Immunogenetics. Dr. Morgan brings more than 30 years of scientific leadership in the life sciences industry.
- Strong balance sheet to advance
Editas Medicine through multiple value inflection points. The Company held cash, cash equivalents, and marketable securities of$337.5 million as ofSeptember 30, 2018 , providing at least 24 months of funding for operating expenses and capital expenditures without any assumption of future cash received from milestones or additional financings.
Upcoming Events
Credit Suisse 27th Annual Healthcare Conference,November 13 ,3:25 p.m. PT ,Phoenix ;- Barclays Gene Editing & Gene Therapy Summit,
November 29 ,1:15 p.m. ET ,New York City ; and - J.P. Morgan 37th Annual Healthcare Conference,
January 7-10, 2019 ,San Francisco
Oral Abstract Number: 409 | |
Title: Comparative Studies Reveal Robust HbF Induction By Editing of HBG1/2 Promoters or BCL11A Erythroid-Enhancer in Human CD34+ Cells but That BCL11A Erythroid-Enhancer Editing Is Associated with Selective Reduction in Erythroid Lineage Reconstitution in a Xenotransplantation Model | |
Presenter: KaiHsin Chang, Ph.D. | |
Session: 112. Thalassemia and Globin Gene Regulation: Hemoglobin Switching | |
Time: Sunday, December 2, 4:30 p.m. | |
Location: San Diego Convention Center, Room 25B |
Third Quarter 2018 Financial Results
Cash, cash equivalents, and marketable securities at
For the third quarter ended
- Collaboration and other research and development revenues were
$14.5 million for the quarter endedSeptember 30, 2018 , compared to$6.3 million for the same period in 2017. The$8.2 million increase was primarily attributable to a$10.6 million increase in revenue recognized pursuant to our strategic alliance withAllergan and$0.1 million in revenue recognized pursuant to a license agreement withBeam Therapeutics, Inc. , partially offset by a$2.4 million decrease in revenue recognized pursuant to our collaboration agreement withJuno Therapeutics, Inc. , aCelgene company and wholly-owned subsidiary ofCelgene Corporation .
- Research and development expenses were
$17.4 million for the quarter endedSeptember 30, 2018 , compared to$20.4 million for the same period in 2017. The$3.0 million decrease was primarily attributable to$4.9 million in decreased sublicensing expenses and$1.0 million in decreased process and platform development expenses, mostly related to reimbursable expenses related to theAllergan profit-sharing arrangement. These decreases were partially offset by$1.3 million in increased employee related expenses,$1.1 million in increased stock-based compensation expenses,$0.3 million in increased facility-related expenses and$0.3 million in increased other expenses.
- General and administrative expenses were
$13.3 million for the quarter endedSeptember 30, 2018 , compared to$12.6 million for the same period in 2017. The$0.7 million increase was primarily attributable to$1.2 million in increased stock-based compensation expenses,$1.1 million in increased employee related expenses,$0.7 million in increased professional service expenses and$0.2 million in increased other expenses, partially offset by$2.4 million in decreased intellectual property and patent related fees.
Conference Call
The
About
As a leading genome editing company,
About EDIT-101
EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber Congenital Amaurosis type 10 (LCA10). EDIT-101 is an AAV5 construct and is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.
About Leber Congenital Amaurosis
Leber Congenital Amaurosis, or LCA, is a group of inherited retinal degenerative disorders caused by mutations in at least 18 different genes. It is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide. Symptoms of LCA appear within the first years of life, resulting in significant vision loss and potentially blindness. The most common form of the disease, LCA10, is a monogenic disorder caused by mutations in the CEP290 gene and is the cause of disease in approximately 20‑30 percent of all LCA patients.
About
In
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company planning to present data and the Company developing and bringing transformative medicines to patients. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the
Editas Medicine, Inc. | ||||||||
Condensed Consolidated Statements of Operations | ||||||||
(unaudited) | ||||||||
(amounts in thousands, except per share and share data) | ||||||||
Three Months Ended | ||||||||
September 30, | ||||||||
2018 | 2017 | |||||||
Collaboration and other research and development revenues | $ | 14,519 | $ | 6,282 | ||||
Operating expenses: | ||||||||
Research and development | 17,443 | 20,396 | ||||||
General and administrative | 13,334 | 12,635 | ||||||
Total operating expenses | 30,777 | 33,031 | ||||||
Operating loss | (16,258 | ) | (26,749 | ) | ||||
Other income, net: | ||||||||
Other (expense) income, net | (4 | ) | 196 | |||||
Interest income (expense), net | 1,024 | (46 | ) | |||||
Total other income, net | 1,020 | 150 | ||||||
Net loss | $ | (15,238 | ) | $ | (26,599 | ) | ||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.32 | ) | $ | (0.64 | ) | ||
Weighted-average common shares outstanding, basic and diluted | 47,414,271 | 41,307,092 | ||||||
Editas Medicine, Inc. | |||||||
Selected Condensed Consolidated Balance Sheet Items | |||||||
(unaudited) | |||||||
(amounts in thousands) | |||||||
September 30, | December 31, | ||||||
2018 | 2017 | ||||||
Cash, cash equivalents, and marketable securities | $ | 337,492 | $ | 329,139 | |||
Working capital | 316,467 | 295,492 | |||||
Total assets | 387,630 | 373,260 | |||||
Deferred revenue, net of current portion | 104,100 | 94,725 | |||||
Construction financing lease obligation, net of current portion | 32,694 | 33,431 | |||||
Total stockholders’ equity | 224,449 | 208,080 | |||||
Media Contact
(617) 401-0113
cristi.barnett@editasmed.com
Investor Contact
(617) 401-9083
mark.mullikin@editasmed.com
Source: Editas Medicine, Inc.